‘‘(VI) urging physicians to use 
the drug in the treatment of addic-
tion; and 
‘‘(VII) 
encouraging 
insurance 
companies to reimburse the cost of 
the drug for the treatment of addic-
tion. 
‘‘(xi) An assessment of Federal effec-
tiveness in achieving the National Drug 
Control Strategy for the previous year, in-
cluding a specific evaluation of whether the 
objectives and targets for reducing illicit 
drug use for the previous year were met 
and reasons for the success or failure of 
the previous year’s Strategy. 
‘‘(xii) A general review of the status 
of, and trends in, demand reduction activi-
ties by private sector entities and commu-
nity-based organizations, including faith-
based organizations, to determine their ef-
fectiveness and the extent of cooperation, 
coordination, and mutual support between 
such entities and organizations and Fed-
eral, State, local, and tribal government 
agencies.
‘‘(xiii) Such additional statistical data 
and information as the Director considers 
appropriate to demonstrate and assess 
trends relating to illicit drug use, the ef-
fects and consequences of illicit drug use 
(including the effects on children of sub-
stance abusers), supply reduction, demand 
reduction, drug-related law enforcement, 
and the implementation of the National 
Drug Control Strategy. 
‘‘(xiv) A supplement reviewing the ac-
tivities of each individual National Drug 
Control Program agency during the pre-
vious year with respect to the National 
Drug Control Strategy and the Director’s 
assessment of the progress of each Na-
tional Drug Control Program agency in 
meeting its responsibilities under the Na-
tional Drug Control Strategy. 
‘‘(B) 
CLASSIFIED
INFORMATION.—Any 
contents of the National Drug Control Strategy 
that involve information properly classified 
under criteria established by an Executive order 
shall be presented to Congress separately from 
the rest of the National Drug Control Strategy.
‘‘(C) SELECTION OF DATA AND INFORMA-
TION.—In selecting data and information for 
inclusion under subparagraph (A), the Director 
shall ensure—
‘‘(i) the inclusion of data and informa-
tion that will permit analysis of current 
trends against previously compiled data 
and information where the Director be-
lieves such analysis enhances long-term as-
sessment of the National Drug Control 
Strategy; and 
‘‘(ii) the inclusion of data and infor-
mation to permit a standardized and uni-
form assessment of the effectiveness of 
drug treatment programs in the United 
States. 
‘‘(3) PROCESS FOR DEVELOPMENT AND SUB-
MISSION.—In developing and effectively imple-
menting the National Drug Control Strategy, the 
Director—
‘‘(A) shall consult with—
‘‘(i) the heads of the National Drug 
Control Program agencies; 
‘‘(ii) Congress; 
‘‘(iii) State, local, and tribal officials;
‘‘(iv) private citizens and organiza-
tions, including community and faith-based 
organizations with experience and expertise 
in demand reduction; 
‘‘(v) private citizens and organizations 
with experience and expertise in supply re-
duction; and 
‘‘(vi) appropriate representatives of 
foreign governments; 
‘‘(B) in satisfying the requirements of sub-
paragraph (A), shall ensure, to the maximum 
extent possible, that State, local, and tribal offi-
cials and relevant private organizations commit 
to support and take steps to achieve the goals 
and objectives of the National Drug Control 
Strategy; 
‘‘(C) with the concurrence of the Attorney 
General, may require the El Paso Intelligence 
Center to undertake specific tasks or projects to 
support or implement the National Drug Con-
trol Strategy; and 
‘‘(D) with the concurrence of the Director 
of National Intelligence and the Attorney Gen-
eral, may request that the National Drug Intel-
ligence Center undertake specific tasks or
projects to support or implement the National 
Drug Control Strategy. 
‘‘(b) SUBMISSION
OF REVISED STRATEGY.—The 
President may submit to Congress a revised National 
Drug Control Strategy that meets the requirements of this 
section—
‘‘(1) at any time, upon a determination of the 
President, in consultation with the Director, that the 
National Drug Control Strategy in effect is not suf-
ficiently effective; or 
‘‘(2) if a new President or Director takes of-
fice.’’. 
SEC. 202. PERFORMANCE MEASUREMENTS. 
Section 706 is amended by adding at the end the fol-
lowing: 
‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—Not 
later than February 1 of each year, the Director shall sub-
mit to Congress as part of the National Drug Control 
Strategy, a description of a national drug control perform-
ance measurement system, that—
‘‘(1) develops 2-year and 5-year performance 
measures and targets for each National Drug Con-
trol Strategy goal and objective established for re-
ducing drug use, availability, and the consequences 
of drug use;
‘‘(2) describes the sources of information and 
data that will be used for each performance measure 
incorporated into the performance measurement sys-
tem; 
‘‘(3) identifies major programs and activities of 
the National Drug Control Program agencies that 
support the goals and annual objectives of the Na-
tional Drug Control Strategy; 
‘‘(4) evaluates the contribution of demand re-
duction and supply reduction activities as defined in 
section 702 implemented by each National Drug 
Control Program agency in support of the National 
Drug Control Strategy; 
‘‘(5) monitors consistency between the drug-re-
lated goals and objectives of the National Drug Con-
trol Program agencies and ensures that each agen-
cy’s goals and budgets support and are fully con-
sistent with the National Drug Control Strategy; 
and 
‘‘(6) coordinates the development and imple-
mentation of national drug control data collection 
and reporting systems to support policy formulation 
and performance measurement, including an assess-
ment of—
‘‘(A) the quality of current drug use meas-
urement instruments and techniques to measure 
supply reduction and demand reduction activi-
ties; 
‘‘(B) the adequacy of the coverage of exist-
ing national drug use measurement instruments 
and techniques to measure the illicit drug user 
population, and groups that are at risk for il-
licit drug use; 
‘‘(C) the adequacy of the coverage of exist-
ing national treatment outcome monitoring sys-
tems to measure the effectiveness of drug abuse 
treatment in reducing illicit drug use and crimi-
nal behavior during and after the completion of 
substance abuse treatment; and 
‘‘(D) the actions the Director shall take to 
correct any deficiencies and limitations identi-
fied pursuant to subparagraphs (A) and (B) of 
this subsection. 
‘‘(d) MODIFICATIONS.—A description of any modi-
fications made during the preceding year to the national 
drug performance measurement system described in sub-
section (c) shall be included in each report submitted 
under subsection (b).’’.
SEC. 203. ANNUAL REPORT REQUIREMENT. 
(a) IN GENERAL.—On or before February 1 of each 
year, the Director shall submit a report to Congress that 
describes—
(1) the strategy of the national media campaign 
and whether specific objectives of the campaign were 
accomplished; 
(2) steps taken to ensure that the national 
media campaign operates in an effective and effi-
cient manner consistent with the overall strategy 
and focus of the campaign; 
(3) plans to purchase advertising time and 
space; 
(4) policies and practices implemented to ensure 
that Federal funds are used responsibly to purchase 
advertising time and space and eliminate the poten-
tial for waste, fraud, and abuse; 
(5) all contracts entered into with a corpora-
tion, partnership, or individual working on behalf of 
the national media campaign; 
(6) specific policies and steps implemented to 
ensure compliance with title IV of this Act; 
(7) steps taken to ensure that the national 
media campaign will secure, to the maximum extent 
possible, no cost matches of advertising time and 
space or in-kind contributions that are directly re-
lated to the campaign in accordance with title IV of 
this Act; and 
(8) a review and evaluation of the effectiveness 
of the national media campaign strategy for the past 
year. 
(b) AUDIT.—The Government Accountability Office 
shall, at a frequency of not less than once per year—
(1) conduct and supervise an audit and inves-
tigation relating to the programs and operations of 
the—
(A) Office; or 
(B) certain programs within the Office, in-
cluding—
(i) the High Intensity Drug Traf-
ficking Areas Program; 
(ii) the Counterdrug Technology As-
sessment Center; or 
(iii) the National Youth Anti-drug 
Media Campaign; and 
(2) provide the Director and the appropriate 
congressional committees with a report containing 
an evaluation of and recommendations on the—
(A) policies and activities of the programs 
and operations subject to the audit and inves-
tigation;
(B) economy, efficiency, and effectiveness 
in the administration of the reviewed programs 
and operations; and 
(C) policy or management changes needed 
to prevent and detect fraud and abuse in such 
programs and operations. 
TITLE III—HIGH INTENSITY 
DRUG TRAFFICKING AREAS 
SEC. 301. HIGH INTENSITY DRUG TRAFFICKING AREAS 
PROGRAM. 
Section 707 is amended to read as follows: 
‘‘SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS 
PROGRAM. 
‘‘(a) ESTABLISHMENT.—
‘‘(1) IN GENERAL.—There is established in the 
Office a program to be known as the High Intensity 
Drug Trafficking Areas Program (in this section re-
ferred to as the ‘Program’). 
‘‘(2) PURPOSE.—The purpose of the Program 
is to reduce drug trafficking and drug production in 
the United States by—
‘‘(A) facilitating cooperation among Fed-
eral, State, local, and tribal law enforcement 
agencies to share information and implement 
coordinated enforcement activities;
‘‘(B) enhancing law enforcement intel-
ligence sharing among Federal, State, local, and 
tribal law enforcement agencies; 
‘‘(C) providing reliable law enforcement in-
telligence to law enforcement agencies needed to 
design effective enforcement strategies and op-
erations; and 
‘‘(D) supporting coordinated law enforce-
ment strategies which maximize use of available 
resources to reduce the supply of illegal drugs 
in designated areas and in the United States as 
a whole. 
‘‘(b) DESIGNATION.—
‘‘(1) IN GENERAL.—The Director, in consulta-
tion with the Attorney General, the Secretary of the 
Treasury, the Secretary of Homeland Security, 
heads of the National Drug Control Program agen-
cies, and the Governor of each applicable State, may 
designate any specified area of the United States as 
a high intensity drug trafficking area. 
‘‘(2) ACTIVITIES.—After making a designation 
under paragraph (1) and in order to provide Federal 
assistance to the area so designated, the Director 
may—
‘‘(A) obligate such sums as are appro-
priated for the Program; 
‘‘(B) direct the temporary reassignment of 
Federal personnel to such area, subject to the 
approval of the head of the department or agen-
cy that employs such personnel; 
‘‘(C) take any other action authorized 
under section 704 to provide increased Federal 
assistance to those areas; and 
‘‘(D) coordinate activities under this sec-
tion (specifically administrative, recordkeeping, 
and funds management activities) with State, 
local, and tribal officials. 
‘‘(c) PETITIONS FOR DESIGNATION.—The Director 
shall establish regulations under which a coalition of inter-
ested law enforcement agencies from an area may petition 
for designation as a high intensity drug trafficking area. 
Such regulations shall provide for a regular review by the 
Director of the petition, including a recommendation re-
garding the merit of the petition to the Director by a panel 
of qualified, independent experts. 
‘‘(d) FACTORS FOR CONSIDERATION.—In considering 
whether to designate an area under this section as a high 
intensity drug trafficking area, the Director shall consider,
in addition to such other criteria as the Director considers 
to be appropriate, the extent to which—
‘‘(1) the area is a significant center of illegal 
drug production, manufacturing, importation, or dis-
tribution; 
‘‘(2) State, local, and tribal law enforcement 
agencies have committed resources to respond to the 
drug trafficking problem in the area, thereby indi-
cating a determination to respond aggressively to the 
problem; 
‘‘(3) drug-related activities in the area are hav-
ing a significant harmful impact in the area, and in 
other areas of the country; and 
‘‘(4) a significant increase in allocation of Fed-
eral resources is necessary to respond adequately to 
drug-related activities in the area. 
‘‘(e) ORGANIZATION
OF HIGH INTENSITY DRUG 
TRAFFICKING AREAS.—
‘‘(1) EXECUTIVE
BOARD
AND
OFFICERS.—To 
be eligible for funds appropriated under this section, 
each high intensity drug trafficking area shall be 
governed by an Executive Board. The Executive 
Board shall designate a chairman, vice chairman, 
and any other officers to the Executive Board that 
it determines are necessary.
‘‘(2) RESPONSIBILITIES.—The Executive Board 
of a high intensity drug trafficking area shall be re-
sponsible for—
‘‘(A) providing direction and oversight in 
establishing and achieving the goals of the high 
intensity drug trafficking area; 
‘‘(B) managing the funds of the high in-
tensity drug trafficking area; 
‘‘(C) reviewing and approving all funding 
proposals consistent with the overall objective of 
the high intensity drug trafficking area; and 
‘‘(D) reviewing and approving all reports 
to the Director on the activities of the high in-
tensity drug trafficking area. 
‘‘(3) BOARD REPRESENTATION.—None of the 
funds appropriated under this section may be ex-
pended for any high intensity drug trafficking area, 
or for a partnership or region of a high intensity 
drug trafficking area, if the Executive Board for 
such area, region, or partnership, does not apportion 
an equal number of votes between representatives of 
participating Federal agencies and representatives of 
participating State, local, and tribal agencies. Where 
it is impractical for an equal number of representa-
tives of Federal agencies and State, local, and tribal
agencies to attend a meeting of an Executive Board 
in person, the Executive Board may use a system of 
proxy votes or weighted votes to achieve the voting 
balance required by this paragraph. 
‘‘(4) NO
AGENCY
RELATIONSHIP.—The eligi-
bility requirements of this section are intended to 
ensure the responsible use of Federal funds. Nothing 
in this section is intended to create an agency rela-
tionship between individual high intensity drug traf-
ficking areas and the Federal Government. 
‘‘(f) USE OF FUNDS.—The Director shall ensure that 
no Federal funds appropriated for the Program are ex-
pended for the establishment or expansion of drug treat-
ment programs, and shall ensure that not more than 5 
percent of the Federal funds appropriated for the Pro-
gram are expended for the establishment of drug preven-
tion programs. 
‘‘(g) COUNTERTERRORISM ACTIVITIES.—
‘‘(1) ASSISTANCE AUTHORIZED.—The Director 
may authorize use of resources available for the Pro-
gram to assist Federal, State, local, and tribal law 
enforcement agencies in investigations and activities 
related to terrorism and prevention of terrorism, es-
pecially but not exclusively with respect to such in-
vestigations and activities that are also related to 
drug trafficking. 
‘‘(2) LIMITATION.—The Director shall ensure—
‘‘(A) that assistance provided under para-
graph (1) remains incidental to the purpose of 
the Program to reduce drug availability and 
carry out drug-related law enforcement activi-
ties; and 
‘‘(B) that significant resources of the Pro-
gram are not redirected to activities exclusively 
related to terrorism, except on a temporary 
basis under extraordinary circumstances, as de-
termined by the Director. 
‘‘(h) ROLE OF DRUG ENFORCEMENT ADMINISTRA-
TION.—The Director, in consultation with the Attorney 
General, shall ensure that a representative of the Drug 
Enforcement Administration is included in the Intelligence 
Support Center for each high intensity drug trafficking 
area. 
‘‘(i) ANNUAL HIDTA PROGRAM BUDGET SUBMIS-
SIONS.—As part of the documentation that supports the 
President’s annual budget request for the Office, the Di-
rector shall submit to Congress a budget justification that 
includes—
‘‘(1) the amount proposed for each high inten-
sity drug trafficking area, conditional upon a review 
by the Office of the request submitted by the 
HIDTA and the performance of the HIDTA, with 
supporting narrative descriptions and rationale for 
each request; 
‘‘(2) a detailed justification that explains—
‘‘(A) the reasons for the proposed funding 
level; how such funding level was determined 
based on a current assessment of the drug traf-
ficking threat in each high intensity drug traf-
ficking area; 
‘‘(B) how such funding will ensure that the 
goals and objectives of each such area will be 
achieved; and 
‘‘(C) how such funding supports the Na-
tional Drug Control Strategy; and 
‘‘(3) the amount of HIDTA funds used to in-
vestigate and prosecute organizations and individ-
uals trafficking in methamphetamine in the prior 
calendar year, and a description of how those funds 
were used. 
‘‘(j) EMERGING THREAT RESPONSE FUND.—
‘‘(1) IN GENERAL.—Subject to the availability 
of appropriations, the Director may expend up to 10
percent of the amounts appropriated under this sec-
tion on a discretionary basis, to respond to any 
emerging drug trafficking threat in an existing high 
intensity drug trafficking area, or to establish a new 
high intensity drug trafficking area or expand an ex-
isting high intensity drug trafficking area, in accord-
ance with the criteria established under paragraph 
(2). 
‘‘(2) CONSIDERATION
OF
IMPACT.—In allo-
cating funds under this subsection, the Director 
shall consider—
‘‘(A) the impact of activities funded on re-
ducing overall drug traffic in the United States, 
or minimizing the probability that an emerging 
drug trafficking threat will spread to other 
areas of the United States; and 
‘‘(B) such other criteria as the Director 
considers appropriate. 
‘‘(k) EVALUATION.—
‘‘(1) INITIAL REPORT.—Not later than 90 days 
after the date of the enactment of this section, the 
Director shall, after consulting with the Executive 
Boards of each designated high intensity drug traf-
ficking area, submit a report to Congress that de-
scribes, for each designated high intensity drug traf-
ficking area—
‘‘(A) the specific purposes for the high in-
tensity drug trafficking area; 
‘‘(B) the specific long-term and short-term 
goals and objectives for the high intensity drug 
trafficking area; 
‘‘(C) the measurements that will be used to 
evaluate the performance of the high intensity 
drug trafficking area in achieving the long-term 
and short-term goals; and 
‘‘(D) the reporting requirements needed to 
evaluate the performance of the high intensity 
drug trafficking area in achieving the long-term 
and short-term goals. 
‘‘(2) EVALUATION OF HIDTA PROGRAM AS PART 
OF NATIONAL DRUG CONTROL STRATEGY.—For each 
designated high intensity drug trafficking area, the 
Director shall submit, as part of the annual National 
Drug Control Strategy report, a report that—
‘‘(A) describes—
‘‘(i) the specific purposes for the high 
intensity drug trafficking area; and
‘‘(ii) the specific long-term and short-
term goals and objectives for the high in-
tensity drug trafficking area; and 
‘‘(B) includes an evaluation of the per-
formance of the high intensity drug trafficking 
area in accomplishing the specific long-term 
and short-term goals and objectives identified 
under paragraph (1)(B). 
‘‘(l) ASSESSMENT OF DRUG ENFORCEMENT TASK 
FORCES
IN
HIGH
INTENSITY
DRUG
TRAFFICKING 
AREAS.—Not later than 1 year after the date of enact-
ment of this subsection, and as part of each subsequent 
annual National Drug Control Strategy report, the Direc-
tor shall submit to Congress a report—
‘‘(1) assessing the number and operation of all 
federally funded drug enforcement task forces within 
each high intensity drug trafficking area; and 
‘‘(2) describing—
‘‘(A) each Federal, State, local, and tribal 
drug enforcement task force operating in the 
high intensity drug trafficking area; 
‘‘(B) how such task forces coordinate with 
each other, with any high intensity drug traf-
ficking area task force, and with investigations
receiving funds from the Organized Crime and 
Drug Enforcement Task Force; 
‘‘(C) what steps, if any, each such task 
force takes to share information regarding drug 
trafficking and drug production with other fed-
erally funded drug enforcement task forces in 
the high intensity drug trafficking area; 
‘‘(D) the role of the high intensity drug 
trafficking area in coordinating the sharing of 
such information among task forces; 
‘‘(E) the nature and extent of cooperation 
by each Federal, State, local, and tribal partici-
pant in ensuring that such information is 
shared among law enforcement agencies and 
with the high intensity drug trafficking area; 
‘‘(F) the nature and extent to which infor-
mation sharing and enforcement activities are 
coordinated with joint terrorism task forces in 
the high intensity drug trafficking area; and 
‘‘(G) any recommendations for measures 
needed to ensure that task force resources are 
utilized efficiently and effectively to reduce the 
availability of illegal drugs in the high intensity 
drug trafficking areas.
‘‘(m) ASSESSMENT OF LAW ENFORCEMENT INTEL-
LIGENCE SHARING
IN HIGH INTENSITY DRUG TRAF-
FICKING AREAS PROGRAM.—Not later than 180 days 
after the date of the enactment of this section, and as part 
of each subsequent annual National Drug Control Strat-
egy report, the Director, in consultation with the Director 
of National Intelligence, shall submit to Congress a re-
port—
‘‘(1) evaluating existing and planned law en-
forcement intelligence systems supported by each 
high intensity drug trafficking area, or utilized by 
task forces receiving any funding under the Pro-
gram, including the extent to which such systems 
ensure access and availability of law enforcement in-
telligence to Federal, State, local, and tribal law en-
forcement agencies within the high intensity drug 
trafficking area and outside of it; 
‘‘(2) the extent to which Federal, State, local, 
and tribal law enforcement agencies participating in 
each high intensity drug trafficking area are sharing 
law enforcement intelligence information to assess 
current drug trafficking threats and design appro-
priate enforcement strategies; and 
‘‘(3) the measures needed to improve effective 
sharing of information and law enforcement intel-
ligence regarding drug trafficking and drug produc-
tion among Federal, State, local, and tribal law en-
forcement participating in a high intensity drug traf-
ficking area, and between such agencies and similar 
agencies outside the high intensity drug trafficking 
area. 
‘‘(n) COORDINATION OF LAW ENFORCEMENT INTEL-
LIGENCE SHARING WITH ORGANIZED CRIME DRUG EN-
FORCEMENT TASK FORCE PROGRAM.—The Director, in 
consultation with the Attorney General, shall ensure that 
any drug enforcement intelligence obtained by the Intel-
ligence Support Center for each high intensity drug traf-
ficking area is shared, on a timely basis, with the drug 
intelligence fusion center operated by the Organized Crime 
Drug Enforcement Task Force of the Department of Jus-
tice. 
‘‘(o) USE OF FUNDS TO COMBAT METHAMPHET-
AMINE TRAFFICKING.—
‘‘(1) REQUIREMENT.—As part of the docu-
mentation that supports the President’s annual 
budget request for the Office, the Director shall sub-
mit to Congress a report describing the use of 
HIDTA funds to investigate and prosecute organiza-
tions and individuals trafficking in methamphet-
amine in the prior calendar year.
‘‘(2) CONTENTS.—The report shall include—
‘‘(A) the number of methamphetamine 
manufacturing facilities discovered through 
HIDTA-funded initiatives in the previous fiscal 
year; 
‘‘(B) the amounts of methamphetamine or 
listed chemicals (as that term is defined in sec-
tion 102(33) of the Controlled Substances Act 
(21 U.S.C. 802(33)) seized by HIDTA-funded 
initiatives in the area during the previous year; 
and 
‘‘(C) law enforcement intelligence and pre-
dictive data from the Drug Enforcement Ad-
ministration showing patterns and trends in 
abuse, trafficking, and transportation in meth-
amphetamine and listed chemicals. 
‘‘(3) CERTIFICATION.—Before the Director 
awards any funds to a high intensity drug traf-
ficking area, the Director shall certify that the law 
enforcement entities participating in that HIDTA 
are providing laboratory seizure data to the national 
clandestine laboratory database at the El Paso Intel-
ligence Center.
‘‘(p) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to the Office of National 
Drug Control Policy to carry out this section—
‘‘(1) $240,000,000 for fiscal year 2007; 
‘‘(2) $250,000,000 for fiscal year 2008; 
‘‘(3) $260,000,000 for fiscal year 2009; 
‘‘(4) $270,000,000 for fiscal year 2010; and 
‘‘(5) $280,000,000 for each of fiscal year 
2011.’’. 
SEC. 302. FUNDING FOR CERTAIN HIGH INTENSITY DRUG 
TRAFFICKING AREAS. 
(a) SHORT TITLE.—This section may be cited as the 
‘‘Dawson Family Community Protection Act’’. 
(b) FINDINGS.—Congress finds the following: 
(1) In the early morning hours of October 16, 
2002, the home of Carnell and Angela Dawson was 
firebombed 
in 
apparent 
retaliation 
for 
Mrs. 
Dawson’s notification to police about persistent drug 
distribution activity in their East Baltimore City 
neighborhood. 
(2) The arson claimed the lives of Mr. and Mrs. 
Dawson and their 5 young children, aged 9 to 14. 
(3) The horrific murder of the Dawson family 
is a stark example of domestic narco-terrorism.
(4) In all phases of counternarcotics law en-
forcement—from prevention to investigation to pros-
ecution to reentry—the voluntary cooperation of or-
dinary citizens is a critical component. 
(5) Voluntary cooperation is difficult for law en-
forcement officials to obtain when citizens feel that 
cooperation carries the risk of violent retaliation by 
illegal drug trafficking organizations and their affili-
ates. 
(6) Public confidence that law enforcement is 
doing all it can to make communities safe is a pre-
requisite for voluntary cooperation among people 
who may be subject to intimidation or reprisal (or 
both). 
(7) Witness protection programs are insufficient 
on their own to provide security because many indi-
viduals and families who strive every day to make 
distressed neighborhoods livable for their children, 
other relatives, and neighbors will resist or refuse of-
fers of relocation by local, State, and Federal pros-
ecutorial agencies and because, moreover, the contin-
ued presence of strong individuals and families is 
critical to preserving and strengthening the social 
fabric in such communities.
(8) Where (as in certain sections of Baltimore 
City) interstate trafficking of illegal drugs has severe 
ancillary local consequences within areas designated 
as high intensity drug trafficking areas, it is impor-
tant that supplementary High Intensity Drug Traf-
ficking Areas Program funds be committed to sup-
port initiatives aimed at making the affected com-
munities safe for the residents of those communities 
and encouraging their cooperation with tribal, local, 
State, and Federal law enforcement efforts to com-
bat illegal drug trafficking. 
(c) FUNDING FOR CERTAIN HIGH INTENSITY DRUG 
TRAFFICKING AREAS.—Section 707, as amended by sec-
tion 301, is amended by adding at the end the following: 
‘‘(q) SPECIFIC PURPOSES.—
‘‘(1) IN GENERAL.—The Director shall ensure 
that, of the amounts appropriated for a fiscal year 
for the Program, at least $7,000,000 is used in high 
intensity drug trafficking areas with severe neigh-
borhood safety and illegal drug distribution prob-
lems. 
‘‘(2) REQUIRED USES.—The funds used under 
paragraph (1) shall be used—
‘‘(A) to ensure the safety of neighborhoods 
and the protection of communities, including
the prevention of the intimidation of potential 
witnesses of illegal drug distribution and related 
activities; and 
‘‘(B) to combat illegal drug trafficking 
through such methods as the Director considers 
appropriate, such as establishing or operating 
(or both) a toll-free telephone hotline for use by 
the public to provide information about illegal 
drug-related activities.’’. 
SEC. 303. ASSESSMENT. 
The Director shall assess the ability of the HIDTA 
Program to respond to the so-called ‘‘balloon effect’’, 
whereby urban drug traffickers facing intensive law en-
forcement efforts expand and spread their trafficking and 
distribution into rural, suburban, and smaller urban areas 
by conducting a demonstration project examining the abil-
ity of the New York/New Jersey HIDTA, with its new sin-
gle colocated Organized Crime and Drug Enforcement 
Task Force/High Intensity Drug Trafficking Area Strike 
Force and HIDTA Regional Intelligence Center, to ad-
dress the movement of drug traffickers into the more 
rural, suburban, and smaller areas encompassed by the 
counties of Albany, Onondaga, Monroe, and Erie in New 
York State and by annexing these counties into the exist-
ing New York/New Jersey HIDTA.
TITLE IV—TECHNOLOGY 
SEC. 401. COUNTERDRUG TECHNOLOGY ASSESSMENT CEN-
TER. 
(a) CHIEF SCIENTIST.—Section 708(b) is amended 
to read as follows: 
‘‘(b) CHIEF SCIENTIST.—There shall be at the head 
of the Center the Chief Scientist, who shall be appointed 
by the Director from among individuals qualified and dis-
tinguished in the area of science, medicine, engineering, 
or technology.’’. 
(b) RESPONSIBILITIES.—
(1) RESEARCH
AND
DEVELOPMENT.—Section 
708 is amended by—
(A) redesignating subsection (d) as sub-
section (e); and 
(B) striking subsection (c) and inserting 
the following: 
‘‘(c) RESEARCH AND DEVELOPMENT RESPONSIBIL-
ITIES.—The Director, acting through the Chief Scientist, 
shall—
‘‘(1) identify and define the short-, medium-, 
and long-term scientific and technological needs of 
Federal, State, local, and tribal drug supply reduc-
tion agencies, including—
‘‘(A) advanced surveillance, tracking, and 
radar imaging; 
‘‘(B) electronic support measures; 
‘‘(C) communications; 
‘‘(D) data fusion, advanced computer sys-
tems, and artificial intelligence; and 
‘‘(E) chemical, biological, radiological (in-
cluding neutron and electron), and other means 
of detection; 
‘‘(2) identify demand reduction basic and ap-
plied research needs and initiatives, in consultation 
with affected National Drug Control Program agen-
cies, including—
‘‘(A) 
improving 
treatment 
through 
neuroscientific advances; 
‘‘(B) improving the transfer of biomedical 
research to the clinical setting; and 
‘‘(C) in consultation with the National In-
stitute of Drug Abuse and the Substance Abuse 
and Mental Health Services Administration, 
and through interagency agreements or grants, 
examining addiction and rehabilitation research 
and the application of technology to expanding 
the effectiveness and availability of drug treat-
ment;
‘‘(3) make a priority ranking of such needs 
identified in paragraphs (1) and (2) according to fis-
cal and technological feasibility, as part of a Na-
tional Counterdrug Research and Development Pro-
gram; 
‘‘(4) oversee and coordinate counterdrug tech-
nology initiatives with related activities of other Fed-
eral civilian and military departments; 
‘‘(5) provide support to the development and 
implementation of the national drug control per-
formance measurement system established under 
subsection (c) of section 706; and 
‘‘(6) pursuant to the authority of the Director 
of National Drug Control Policy under section 704, 
submit requests to Congress for the reprogramming 
or transfer of funds appropriated for counterdrug 
technology research and development. 
‘‘(d) LIMITATION
ON AUTHORITY.—The authority 
granted to the Director under this section shall not extend 
to the awarding of contracts, management of individual 
projects, or other operational activities.’’. 
(2) ASSISTANCE AND SUPPORT.—Subsection (e) 
of section 708, as redesignated by this section, is 
amended to read as follows:
‘‘(e) ASSISTANCE AND SUPPORT TO THE OFFICE OF 
NATIONAL DRUG CONTROL POLICY.—The Secretary of 
Defense, the Secretary of Homeland Security, and the 
Secretary of Health and Human Services shall, to the 
maximum extent practicable, render assistance and sup-
port to the Office and to the Director in the conduct of 
counterdrug technology assessment.’’. 
(3) TECHNOLOGY
TRANSFER
PROGRAM.—Sec-
tion 708 is amended by adding at the end the fol-
lowing: 
‘‘(f) TECHNOLOGY TRANSFER PROGRAM.—
‘‘(1) PROGRAM.—The Chief Scientist, with the 
advice and counsel of experts from State, local, and 
tribal law enforcement agencies, shall be responsible 
to the Director for coordination and implementation 
of a counterdrug technology transfer program. 
‘‘(2) PURPOSE.—The purpose of the Tech-
nology 
Transfer 
Program 
shall 
be 
for 
the 
Counterdrug Technology Assessment Center to 
transfer technology and associated training directly 
to State, local, and tribal law enforcement agencies. 
‘‘(3) PRIORITY OF RECEIPTS.—Transfers shall 
be made in priority order based on—
‘‘(A) the need of potential recipients for 
such technology;
‘‘(B) the effectiveness of the technology to 
enhance current counterdrug activities of poten-
tial recipients; and 
‘‘(C) the ability and willingness of potential 
recipients to evaluate transferred technology. 
‘‘(4) AGREEMENT
AUTHORITY.—The Director 
may enter into an agreement with the Secretary of 
Homeland Security to transfer technology with both 
counterdrug and homeland security applications to 
State, local, and tribal law enforcement agencies on 
a reimbursable basis. 
‘‘(5) REPORT.—On or before July 1 of each 
year, the Director shall submit a report to the ap-
propriate congressional committees that addresses 
the following: 
‘‘(A) The number of requests received dur-
ing the previous 12 months, including the iden-
tity of each requesting agency and the type of 
technology requested. 
‘‘(B) The number of requests fulfilled dur-
ing the previous 12 months, including the iden-
tity of each recipient agency and the type of 
technology transferred. 
‘‘(C) A summary of the criteria used in 
making the determination on what requests